Skip to content

Home
Sectors
News Type
About Us

Latest News

Ioneer Ltd (ASX:INR) Quadruples Ore Reserve and Strengthens Rhyolite Ridge Project

James Hardie (ASX:JHX) Syndicates $3.5B in New Credit Facilities

Axel REE Limited (ASX:AXL) Announces Strategic Leadership Transition

Lunnon Metals (ASX:LM8) Reveals New Gold Structures in Sterilisation Drilling

Merchant House International Limited (ASX:MHI) Announces Preliminary Financial Results for FY2025

New Zealand King Salmon Investments Limited (ASX:NZK) Reduces FY26 Harvest Volumes

Invion Limited (ASX:IVX) Reports Positive Phase I/II Skin Cancer Trial Results

Noxopharm Limited (ASX:NOX) Receives Approval for HERACLES Clinical Trial

Bayan Mining and Minerals (ASX:BMM) Initiates Phase Two Exploration at Bayan Springs Project

St Barbara Limited (ASX:SBM) Confirms 15-Mile Processing Hub Development

Search

The Capital Club

The Hub of Australian Finance News

Home
Sectors
News Type
About Us

Tuesday, June 03, 2025

Category: ASX-NEU

Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans

ASX-NEU Financials Healthcare

Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans

ClubAI 27 May 2025 3:03 pm

Neuren Pharmaceuticals (ASX:NEU) reports a record A$166m income in 2024, driven by DAYBUE sales and initiates Phase 3 trials for NNZ-2591.

Corporate Strategy & Guidance Dividends & Share Buybacks Earnings Reports

Search

Article Categories

Consumer Discretionary
Consumer Staples
Energy
Financials
Healthcare
Industrials
Information Technology
Materials
Real Estate
Telecommunication Services
Uncategorised
Utilities

Publishing Policy
About Us
Author Biography

The Capital Club